JP6533932B2 - 抗体を含む治療用組成物 - Google Patents

抗体を含む治療用組成物 Download PDF

Info

Publication number
JP6533932B2
JP6533932B2 JP2015550818A JP2015550818A JP6533932B2 JP 6533932 B2 JP6533932 B2 JP 6533932B2 JP 2015550818 A JP2015550818 A JP 2015550818A JP 2015550818 A JP2015550818 A JP 2015550818A JP 6533932 B2 JP6533932 B2 JP 6533932B2
Authority
JP
Japan
Prior art keywords
peg
hydrophilic polymer
formulation
polymer chains
biological therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015550818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504369A5 (enExample
JP2016504369A (ja
Inventor
トロールサス，ミカエル
スタンクス，ジョン
スー，ジェイムス
ホッサイニー，シード
スミス，ジョシュア，タケシ
アスカー，シャディド
Original Assignee
アボット カーディオバスキュラー システムズ インコーポレイテッド
アボット カーディオバスキュラー システムズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アボット カーディオバスキュラー システムズ インコーポレイテッド, アボット カーディオバスキュラー システムズ インコーポレイテッド filed Critical アボット カーディオバスキュラー システムズ インコーポレイテッド
Publication of JP2016504369A publication Critical patent/JP2016504369A/ja
Publication of JP2016504369A5 publication Critical patent/JP2016504369A5/ja
Application granted granted Critical
Publication of JP6533932B2 publication Critical patent/JP6533932B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2015550818A 2012-12-28 2013-12-27 抗体を含む治療用組成物 Active JP6533932B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747176P 2012-12-28 2012-12-28
US61/747,176 2012-12-28
PCT/US2013/078102 WO2014106116A2 (en) 2012-12-28 2013-12-27 Delivery of biologic therapeutics

Publications (3)

Publication Number Publication Date
JP2016504369A JP2016504369A (ja) 2016-02-12
JP2016504369A5 JP2016504369A5 (enExample) 2017-02-09
JP6533932B2 true JP6533932B2 (ja) 2019-06-26

Family

ID=50000100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550818A Active JP6533932B2 (ja) 2012-12-28 2013-12-27 抗体を含む治療用組成物

Country Status (5)

Country Link
US (2) US9452138B2 (enExample)
EP (1) EP2938323A2 (enExample)
JP (1) JP6533932B2 (enExample)
CN (1) CN105007896B (enExample)
WO (1) WO2014106116A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
AU2016382786A1 (en) * 2015-12-29 2018-07-19 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
JP2021530480A (ja) * 2018-07-09 2021-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ハイドロゲルにおける放出速度の調整
CN113286579A (zh) * 2018-08-23 2021-08-20 埃里克·F·伯恩斯坦 应用抗vegf化合物和使用这类化合物治疗皮肤病的系统、装置和方法
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用
CN112569359A (zh) * 2019-09-30 2021-03-30 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
US20240269349A1 (en) * 2021-09-09 2024-08-15 Sunbio Inc. Sol-gel conversion over time of 6-arm peg hydrogel

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7908799A (nl) * 1978-12-22 1980-06-24 Tno Werkwijze voor de bereiding van een polymeermengsel, gevormde produkten, verkregen daaruit en polymeer- legering.
US5971953A (en) * 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
US6605273B2 (en) * 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CN1569892A (zh) * 2004-04-30 2005-01-26 新峰生物科技（上海）有限公司 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
EP2014256A1 (en) * 2007-07-12 2009-01-14 Straumann Holding AG Composite bone repair material
US8642737B2 (en) * 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
ES2537411T3 (es) * 2011-04-20 2015-06-08 Carbylan Therapeutics, Inc. Composiciones formadoras de gel in situ

Also Published As

Publication number Publication date
US20140186446A1 (en) 2014-07-03
WO2014106116A8 (en) 2015-06-18
US20170042816A1 (en) 2017-02-16
CN105007896B (zh) 2019-04-09
CN105007896A (zh) 2015-10-28
WO2014106116A3 (en) 2014-07-31
US9452138B2 (en) 2016-09-27
EP2938323A2 (en) 2015-11-04
WO2014106116A2 (en) 2014-07-03
JP2016504369A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
JP6533932B2 (ja) 抗体を含む治療用組成物
Qi et al. Protein–polymer conjugation—moving beyond PEGylation
ES2601211T3 (es) Polímero biorreabsorbible implantable cargado con macromoléculas frágiles
Gustafson et al. Silk-elastinlike protein polymers for matrix-mediated cancer gene therapy
CN112368295B (zh) 离子性自组装肽
CN114269323B (zh) 多价肽缀合物的亲水性接头
JP6317748B2 (ja) タンパク質徐放用の生物分解性ドラッグデリバリーシステム
US20080187568A1 (en) Polymerization with precipitation of proteins for elution in physiological solution
JP2007508250A (ja) 持続性放出製剤における長期作用性分子
US20150099808A1 (en) Amphiphilic copolymers and compositions containing such polymers
TW202241502A (zh) 蛋白質封裝微凝膠之製造
CN121001692A (zh) 退火微凝胶颗粒系统及方法
CN104349788B (zh) 新的疏水蛋白释放系统
US11427641B2 (en) Extended local release of anti-CSFR1 antibodies
EP3723814A1 (en) Stabilization of glucagon by trehalose glycopolymer nanogels
Arlotta Synthesis and Characterization of Therapeutic Antibody Conjugates
JP2025526484A (ja) 心臓及び肺の修復を促進するための組成物及び方法
WO2022146925A1 (en) Extended local release of antibodies
HK1206993B (en) New release system of hydrophobic proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190425

R150 Certificate of patent or registration of utility model

Ref document number: 6533932

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250